Compare GIL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIL | DVA |
|---|---|---|
| Founded | 1946 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.4B |
| IPO Year | 1998 | 1995 |
| Metric | GIL | DVA |
|---|---|---|
| Price | $63.66 | $115.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | $73.86 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 2.3M | 975.3K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | ★ 24.08 | 5.63 |
| EPS | 3.13 | ★ 9.76 |
| Revenue | $3,362,263,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $5.76 | $6.50 |
| Revenue Next Year | $102.54 | $2.97 |
| P/E Ratio | $20.66 | ★ $11.89 |
| Revenue Growth | 4.04 | ★ 5.14 |
| 52 Week Low | $37.16 | $113.97 |
| 52 Week High | $65.43 | $179.60 |
| Indicator | GIL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 39.72 |
| Support Level | $59.94 | $115.91 |
| Resistance Level | $65.43 | $122.40 |
| Average True Range (ATR) | 1.68 | 2.55 |
| MACD | 0.72 | 0.01 |
| Stochastic Oscillator | 80.01 | 12.72 |
Gildan is a vertically integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. Its primary market is the sale of blank T-shirts, sweatshirts, and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels. Brands include Gildan, American Apparel, Comfort Colors, and Goldtoe. Gildan produces most of its clothing at factories in Latin America but has been ramping up production at its new facility in Bangladesh. Incorporated in 1984, the Montreal-based company operates internationally but generates nearly 90% of its sales in the US. Gildan is acquiring its US rival Hanesbrands to bolster its consumer and printwear operations.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.